Advertisement Cardiac Science signs three-year agreement with Syncroness - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Cardiac Science signs three-year agreement with Syncroness

Cardiac Science, a developer of advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, has completed a three-year agreement for product design and engineering services from Colorado-based Syncroness, a design and engineering firm serving the medical devices industry.

Bob Odell, vice president of engineering at Cardiac Science, said: We expect considerable savings and speed-to-market improvements with Syncroness. The agreement increases Cardiac Science’s engineering capacity to manage sustaining activities and new business opportunities.

This will allow seasoned Cardiac Science team members to focus on new customer solutions, revenue opportunities, and new advances in technology. As a result, we’ll be even faster and more responsive to market needs.

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph devices (ECGs), cardiac stress systems and treadmills, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company also sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. The company owns brands like the trusted Burdick, HeartCentrix, Powerheart, and Quinton for cardiac diseases.

Syncroness (Westminster, CO) is a product design firm and develops advanced business processes for engineering that increase profit and performance for the pharmaceutical industries.